|
|
6611 Tributary Street
Baltimore, MD 21224 USA
phone:(410) 631-6300
fax:(410) 631-6338
|
|
| Symbol |
GLFD |
| Exchange |
|
| Founded |
0 |
| Employees |
|
|
|
| www.guilfordpharm.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Products for neurology and hospital markets. |
|
| Management |
| CEO: Craig Smith; CFO: Andrew Jordan |
| |
|
|
|
|
|
|
|
|
|
|
|
| Description |
|
Guilford Pharmaceuticals is a fully integrated pharmaceutical company engaged in the research, development and commercialization of products targeting the neurology and hospital markets. |
|
| Products / Services |
The company currently has two advanced clinical development programs, including GPI 1485, for the treatment of Parkinson's disease and post-prostatectomy erectile dysfunction, and a novel sedative/hypnotic. AQUAVAN Injection. Both AQUAVAN Injection and GPI 1485 are currently in Phase II clinical trials.
GLIADEL Wafer, Guilford's commercial product for brain cancer, is implanted at the time of surgery and delivers chemotherapy directly to the tumor site, minimizing drug exposure to other areas of the body. In February 2003, GLIADEL Wafer received expanded labeling approval from the FDA for use in patients newly diagnosed with malignant glioma in addition to patients with recurrent glioblastoma multiforme.
|
|
|
| Strategy |
Guilford has corporate alliances with Pfizer for the commercial development of its NAALADase inhibitor technology; with Orion Pharma for the Scandinavian marketing of GLIADEL Wafer; with Daiichi Radioisotope Laboratories for the development and marketing of DOPASCAN Injection in parts of Asian and with MAP Medical Technologies for the development, marketing, sales and distribution rights to DOPASCAN Injection in the EU.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
